By Karen Roman Vivani Medical, Inc. (Nasdaq: VANI) announced it finished the placement of NPM-115, its GLP-1 (exenatide) ...
Medical Device Network on MSN2d
Vivani treats first patient with long-lasting drug implant for weight lossA day after announcing a business split-off to focus on weight loss and diabetes implants, Vivani Medical has implanted the ...
Vivani Medical completed enrollment in its LIBERATE-1 trial, testing a six-month GLP-1 implant for weight management.
Vivani Medical (VANI) announced the successful administration of its first GLP-1 or exenatide, implant in the LIBERATE-1 clinical trial. This ...
Medical Device Network on MSN3d
Vivani Medical to spin-off neurostim business Cortigent as public companyCortigent will focus on neuromodulation devices while Vivani presses ahead with its weight loss drug implant. Vivani Medical ...
Vivani Medical, Inc. (NASDAQ:VANI) said it intends to spin off Cortigent, Inc., a division that develops brain implant ...
Vivani Medical (Nasdaq:VANI) announced today that it successfully administered the first GLP-1 implant in its LIBERATE-1 ...
The company wants to create two focused companies dedicated to driving current and future value in their respective ...
There’s a lot to be optimistic about in the Healthcare sector as 2 analysts just weighed in on Monogram Orthopaedics Inc (MGRM – Research ...
ALAMEDA, Calif.--(BUSINESS WIRE)--Vivani Medical, Inc. (NASDAQ: VANI) (“Vivani” or the “Company”), a clinical-stage biopharmaceutical company developing ...
Vivani Medical, Inc. (NASDAQ: VANI) ("Vivani" or the "Company"), a clinical-stage biopharmaceutical company developing ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback